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Analyzing Somatic Genome Rearrangements
in Human Cancers by Using Whole-Exome Sequencing
Lixing Yang,1,11 Mi-Sook Lee,2,11 Hengyu Lu,3,11 Doo-Yi Oh,2 Yeon Jeong Kim,4,5 Donghyun Park,4,5
Gahee Park,4 Xiaojia Ren,6 Christopher A. Bristow,7 Psalm S. Haseley,1,6 Soohyun Lee,1
Angeliki Pantazi,8 Raju Kucherlapati,6,8 Woong-Yang Park,2,4 Kenneth L. Scott,3,12 Yoon-La Choi,2,9,12,*
and Peter J. Park1,6,10,12,*
Although exome sequencing data are generated primarily to detect single-nucleotide variants and indels, they can also be used to iden-
tify a subset of genomic rearrangements whose breakpoints are located in or near exons. Using>4,600 tumor and normal pairs across 15
cancer types, we identified over 9,000 high confidence somatic rearrangements, including a large number of gene fusions. We find that
the 50 fusion partners of functional fusions are often housekeeping genes, whereas the 30 fusion partners are enriched in tyrosine kinases.
We establish the oncogenic potential of ROR1-DNAJC6 and CEP85L-ROS1 fusions by showing that they can promote cell proliferation
in vitro and tumor formation in vivo. Furthermore, we found that ~4% of the samples havemassively rearranged chromosomes, many of
which are associated with upregulation of oncogenes such as ERBB2 and TERT. Although the sensitivity of detecting structural alter-
ations from exomes is considerably lower than that from whole genomes, this approach will be fruitful for the multitude of exomes
that have been and will be generated, both in cancer and in other diseases.Introduction
Genomic profiling of tumors with high-throughput
sequencing technologies has provided an unprecedented
opportunity for in-depth studies of genome rearrange-
ments. Whole-genome sequencing (WGS) data are now
routinely used for detection of a wide range of rearrange-
ments with base-pair resolution of breakpoints, including
those breakpoints in non-coding regions. These events
are typically identified on the basis of read depth,1 discor-
dant paired-end reads,2 split-read (reads spanning the
breakpoint) alignment,3 genome assembly,4 local assem-
bly,5 or by a combination of these methods.6 RNA-seq
data can be used to interrogate gene fusions when the
fusion is expressed at a sufficiently high amount.
Whole-exome sequencing (WES) data are generated to
detect single-nucleotide variants (SNVs) and small indels.
An enormous number of exomes have been generated by
researchers around the world: the latest release from the
National Heart, Lung, and Blood Institute (NHLBI) Exome
Sequencing Project7 includes 6,500 samples; the Exome
Aggregation Consortium (ExAC), an international collabo-
ration to collect exome data, has more than 60,000 exomes
in its current release. Despite the decreasing cost of WGS,
WES data will continue to be generated because many so-
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is affordable only with a capture-based approach given cur-
rent technologies. An important question, therefore, is
whether genomic rearrangements can also be detected in
exomes. If that were possible, we would be able to identify
a large number of rearrangements with datasets that were
generated for other purposes.
Here, we describe an approach to identify structural var-
iations (SVs) from WES data. In a typical WES protocol,
genomic DNA is sheared into fragments (~150–250 bp),
and those containing exons are enriched by hybridization
with shorter biotinylated probes (~50–100 nucleotides
long). These probes are usually densely tiled across exons,
extending just past the exon-intron boundaries. Thus,
when the breakpoint of an SVoccurs in or near the targeted
region, the DNA fragment that contains the breakpoint
can be captured if there is sufficient overlap between a
probe and the DNA on either side of the breakpoint
(Figure 1A). The sensitivity of detection fromWES is clearly
much lower than that from WGS, given that just a subset
of rearrangements with breakpoints in or near exons can
be detected and the fragment capture process introduces
inefficiencies. However, with the large number of available
exomes and the higher coverage than WGS, we demon-
strate that re-analyzing existing large-scale WES data for
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Figure 1. Detecting Somatic SVs from WES Data
(A) Workflow showing how DNA fragments are captured and sequenced when SV breakpoints occur in exons and near exon-intron
boundaries.
(B) A true somaticCCDC6-RET fusion resulting from a balanced inversion (chr10:61,655,977–43,611,997) in a thyroid cancer (TCGA-FK-
A3SE) is detected by bothWES andWGS. The scheme of the inversion is shown on the top (not to scale). The Integrated Genome Viewer
screen shot for the captured breakpoint is shown on the bottom. Green and purple read pairs represent discordant pairs from two
different breakpoints; one breakpoint is captured by WES and the other is not. The gray reads are concordant read pairs. The half-
gray and half-striped reads with green or purple outlines are partially aligned (clipped) reads spanning the breakpoints.
(C) A Venn diagram showing the overlap between somatic SVs called from WES and WGS data.
(D) A true somatic deletion (chr18:71,930,713–71,958,983) in a lung adenocarcinoma (TCGA-91-6840) is detected by WES but not by
WGS and is validated by PCR. The coverage in WES is >1003 and there are six discordant read pairs (two displayed), whereas the
coverage of WGS in the same region is 303 and no discordant read pair is present. The red reads are discordant read pairs supporting
the somatic deletion.We applied our proposed method to survey somatic SVs
in 4,609 samples across 15 tumor types from The Cancer
Genome Atlas (TCGA). We focus on somatic variants
here, but the approach we describe applies to detection
of both germline and somatic rearrangements. We chose
the TCGA data because they are high-quality, multi-
dimensional data from a large number of samples,
including cases that have undergone both WES and
WGS. The availability of these two data types for the
same samples allows us to characterize the sensitivity and
specificity of exome-based SV detection. Although
exome-based fusion detection has been recently used to
identify recurrent NAB2-STAT6 (MIM: 602381 and
601512) fusion in solitary fibrous tumors,8 our study ex-
pands this approach to a much larger scale to discover
additional cancer-driving gene fusions and characterize
their features. Our results demonstrate the association of844 The American Journal of Human Genetics 98, 843–856, May 5, 2oncogene upregulation with massive rearrangements. We
also report experimental validation that two of the candi-
date fusions we identified are cancer drivers, including
the report of an activating genetic event related to ROR1
(MIM: 602336).Material and Methods
TCGA Sample Acquisition and WES
The details of data production were described in a previous publi-
cation.9 The procedures followed were in accordance with the
ethical standards of the responsible committee on human experi-
mentation (institutional and national). Tumor samples were ob-
tained from the TCGA network with appropriate consent from
the relevant institutional review board. Tumors were resected,
flash-frozen, and shipped to a centralized processing center (Bio-
specimen Core Resource) for additional pathologic review and016
extraction of nucleic acids. The three genome sequencing centers
(Baylor Human Genome Sequencing Center, Broad Institute, and
The Genome Institute at Washington University) collectively
sequenced the exomes from tumor tissues and matched normal
tissues (mostly blood samples). Exome capturing procedures differ
among sequencing centers and evolve over time. The details can
be found in individual TCGA marker papers. Sequencing reads
were aligned to the reference genome with the Burrows-Wheeler
Aligner,10 and quality control was performed. A single BAM file
that includes reads, calibrated quantities, and alignments to the
genome was generated for each sample.
Data Access
All primary sequence files can be downloaded by registered users
from CGHub. Clinical data are available through the TCGA Data
Portal. All coordinates are based on the hg19 human reference
genome, downloaded from the UCSC Genome Browser.
Detecting Somatic Genome Rearrangements in
WES Data
Somatic genome rearrangements were called by Meerkat, a soft-
ware package we developed.6 In brief, all discordant read pairs
(reads that do not form a proper pair with expected orientations
and distance between the reads) are first identified from the
BAM files. Then, discordant read pairs supporting the same
breakpoint are merged into clusters, which are used to call SV can-
didates. Reads spanning SV breakpoints (clipped reads and
unmapped reads) are mapped back to the SV candidates (split-
read mapping). Breakpoints are refined to the basepair resolution
once split-read supports are identified. Variants are filtered by a
large database of germline variants obtained by merging all
matched normal BAM files from different tumor types together.
The final somatic variants must have discordant read-pair support
and split-read support totaling at least six reads and/or read pairs,
with at least three discordant read-pair support. We have previ-
ously used these criteria to identify somatic SVs from WGS sam-
ples and have demonstrated that such a workflow offers great
sensitivity and specificity. Samples with >100 somatic SVs were
discarded from further analysis. Additional filters were applied to
obtain high-confidence somatic rearrangements: at least four sup-
porting discordant read pairs were required for each somatic event,
and the size of an intra-chromosomal event could not be less than
20 kb. For comparison with WGS results, if the somatic rearrange-
ment detected from WES data and the one detected from WGS
data were the same type of event on the same chromosome(s)
and the breakpoints differed by less than 50 bp, they were consid-
ered to be the same event. In most cases, the breakpoints predicted
from WES and WGS were exactly the same. PCR primers were de-
signed by Primer3.11
Detecting Activating Gene Fusions
RNAwas extracted, prepared into Illumina TruSeqmRNA libraries,
and sequenced by an Illumina sequencing platformwith a target of
60 million read pairs per tumor (48 bp paired-end reads) and sub-
jected to quality control. RNA reads were aligned to the reference
genome with Mapsplice.12 Gene expression was quantified for
the transcriptmodels (TCGAGAF2.1)withRSEM13 andnormalized
within sample to a fixed upper quartile of total reads. RNA-seq re-
sults (normalized gene-level expression and exon-level expression)
were downloaded from the Genome Data Analysis Center at the
Broad Institute. RNA data were available only for tumor tissuesThe Ambecause TCGA collected blood (rather than adjacent normal tis-
sues, which are generally unavailable) as thematched normal con-
trol for the majority of the cases. Therefore, to normalize exonic
expression, we computed a Z score for each exon on the basis of
its expression across all samples in that tumor type.GeneOntology
(GO) term enrichment analyses were performed with DAVID.14 All
50 and 30 fusion partners were entered into DAVID as a gene list to
identify over-represented GO categories, and the functional anno-
tation clustering of GO terms was performed. The p value was
calculated by one-tail Fisher’s exact test.
Analysis of Massive Rearrangements
A binomial model was used to identify the samples in which the
number of somatic rearrangement breakpoints observed on one
chromosome significantly exceeded the expected number, given
the total number of somatic rearrangement breakpoints in one
sample (the likelihood of observing at least n breakpoints on one
chromosome given the total N breakpoints in that sample, with
the probability p being the mappable coding-sequence (CDS)
size for the chromosome divided by the mappable CDS size for
the whole genome). Bonferroni correction was used to adjust for
multiple testing. The mappability of the reference genome was
downloaded from UCSC Genome browser and was used to
normalize the chromosome size.
Statistical Analysis
All statistical analyses were conducted in R package (v.2.14.1).
A p value of 0.01 was used for statistical significance.
Fusion Gene Cloning
Constructs of CEP85L-ROS1(C9;R36) (MIM: 165020), GOPC (MIM:
606845)-ROS1(G7;R35), and EML4 (MIM: 607442)-ALK (MIM:
105590) gene fusions were synthesized by CosmogeneTech and
then transferred into pLenti6.3/V5-DEST (Life Technologies) and
pLenti6.3-EF1a lentiviral vectors. ROR1-DNAJC6 (MIM: 608375)
fusion fragments were cloned from cDNA prepared from U87MG
cells with overlapping ends, fused ROR1-DNAJC6 was then gener-
ated by overlap-extension PCR, and the resulting fusion gene was
then transferred into the pLenti6.3/V5-DEST vector. Expression of
the ROR1-DNAJC6 fusion gene was confirmed via RT-PCR and
western blots with the following primer sets: forward, ROR1,
50-GTGATGAAGATGGGACTGTGAA-30; reverse, DNAJC6, 50-CTA
GAAGATGTGTCTTTGAGGGTGT-30.
Ba/F3 Cell Viability and Inhibitor Assays
The Ba/F3 cell line wasmaintained in RPMI 1640mediumwith 5%
fetal bovine serum and 2.5 ng/ml recombinant mouse IL-3.
CEP85L-ROS1, BCR (MIM: 151410) -ABL ([MIM: 189980] positive
control), and GFP (negative control) were transduced into Ba/F3
cells. At 72 hr post-transduction, cells were re-suspended in
medium without IL-3. Cell viability was determined with Cell
Titer-Glo (Promega) at 7 days after IL-3 depletion. Ba/F3 cells sta-
bly expressing CEP85L-ROS1 (no IL-3 medium) and parental
Ba/F3 cells (IL-3 medium) were seeded in 96-well plates in quadru-
plicates at 1,000 cells per well. For the dose-dependent inhibitor
assay, cells were treated with dimethyl sulfoxide (DMSO) or crizo-
tinib (5 nM to 0.5 mM) and cell viability was determined with Cell
Titer-Glo (Promega). Cell survival was normalized to non-treated
(DMSO control treated) cells. IC50, which is the concentration of
an inhibitor causing 50% inhibition of cell survival normalized
to non-treated cells, was calculated from a sigmoidal curve. Theerican Journal of Human Genetics 98, 843–856, May 5, 2016 845
response of CEP85L-ROS1-expressing cells (without IL3) to crizoti-
nib was compared to parental cells without treatment of crizotinib
as control. Two independent experiments were performed.
Western Blot
Whole-cell and mouse tumor tissue lysates were prepared with ra-
dioimmunoprecipitation assay (50 mM Tris-HCl, 150 mM NaCl,
1% NP-40, and 0.25% sodium deoxycholate) plus protease inhib-
itors cocktail (GenDepot). Cell and tissue lysates were separated by
SDS-PAGE and transferred to polyvinylidene difluoride mem-
branes. The blots were probed with antibodies for ROS1, phos-
phorylated, and total STAT3 (MIM: 102582), AKT and ERK (Cell
Signaling Technology), and ROR1 (Abcam) were then detected
with chemiluminescent substrate (EMD Millipore). All western
blot images are representative of at least three independent
experiments.
In Vitro Cell Proliferation and Transforming Assays
NIH 3T3 cells were obtained from the Korean Cell Line Bank, and
BEAS-2B cells (ATCC CRL-9609) were obtained from the Amer-
ican Type Culture Collection (Manassas, VA). They were
expanded in DMEM supplemented with 10% FBS, 100 units/ml
penicillin, and 100 mg/ml streptomycin. NIH 3T3 cells and
BEAS-2B cells were transduced with LacZ (negative control),
CEP85L-ROS1, GOPC-ROS1 (positive control), ROR1-DNAJC6,
and EML4-ALK (positive control). Then, stable cell lines were
selected with blasticidin. Cell proliferation was determined by a
EZ-Cytox cell viability assay kit (Daeil Lab Service). The trans-
forming activity was assessed by transformed foci formation in
Matrigel. NIH 3T3 stable cells expressing CEP85L-ROS1, GOPC-
ROS1, and EML4-ALK, and BEAS-2B stable cells expressing
ROR1-DNAJC6 and EML4-ALK were seeded in Matrigel (BD Sci-
ences; 10,000 cells per well), on which medium with 10% FBS
was overlaid. The images of transformed foci were taken after
culturing for 7 or 14 days.
Anchorage Independent Growth Assay
MCF-10A cells were cultured as described previously15 and trans-
duced with CEP85L-ROS1, PIK3CAH1047R (positive control), and
GFP (negative control). Soft agar assays were performed in six-
well plates in triplicate. First, bottom layers were prepared at
0.8%Noble agar (Affymetrix) with completeMCF-10A growthme-
dium. After solidification, 10,000 cells were mixed with 0.45%
agar in complete growth medium and laid on top of the bottom
layer. 2 mL of medium was added in each well after 3 days, and
the medium was refreshed every 3 days. For NIH 3T3 and BEAS-
2B cells expressing LacZ, CEP85L-ROS1, GOPC-ROS1, ROR1-
DNAJC6, and EML4-ALK in 0.35% agar (BD Sciences), 20,000 cells
were seeded on top of 0.5% agar in each well. Cells were cultured
for 14 or 21 days, colonies were stained with 0.05% crystal violet,
and images were taken by phase-contrast microscope (Olympus
CKX41) and analyzed by i-Solution Lite image analysis software,
and cells were counted in ten randomly selected fields.
Xenograft Tumor Formation Assay
All animal experiments were approved by the institutional review
board of SamsungMedical Center. 53 106 cells were re-suspended
in 1:1 PBS andMatrigel (BD Biosciences) and then subcutaneously
injected into the right dorsal flank of six-week-old male nudemice
(Orient Bio). Mice were monitored three times weekly until reach-
ing maximal tumor size (approximately 2 cm 3 2 cm). Mice were846 The American Journal of Human Genetics 98, 843–856, May 5, 2then sacrificed and photographed on day 23 after injection, and
tumors were collected for further analysis.Results
Detecting Somatic SVs in WES
In a standard WES protocol (Figure 1A), probes are
designed to capture coding exons. The enriched exonic re-
gions are subsequently amplified and subjected to paired-
end sequencing. Due to the capturing and amplification
steps, the coverage of resulting sequencing data is uneven
across the genome. SV detection tools using read-depth
information will suffer from this uneven sequencing
coverage, whereas tools that depend on discordant read
pairs and split reads to detect genomic rearrangements
can be used in WES data as long as the breakpoints are
captured and sequenced. We first tested the efficacy of de-
tecting somatic SVs using discordant read pairs and split
reads but not read depth. We selected 120 TCGA samples
that had both WES and WGS data (Table S1) for initial
analysis, with the assumption that somatic SVs called on
both platforms are true positives (example in Figure 1B).
We did not define the truth set purely on the basis of
WGS data because some SVs are missed and some SV calls
are artifacts even in WGS.
A major challenge in reliably identifying somatic SVs in
WES data is to remove a large number of artifacts arising
from chimeric molecules in the library preparation. This
requires designing data processing steps to remove WES-
specific artifacts. When we applied the Meerkat algorithm
we originally developed6 for WGS toWES data, we found a
small subset of the samples containing a large number
(>100) of somatic SVs, with the majority of SVs not found
in the matched WGS (Figure S1A; examples shown in Fig-
ures S1B and S1C). WES-specific artifacts were distinguish-
able by their even distribution across all chromosomes,
enrichment of small tandem duplications, and no homol-
ogy at the breakpoints (Figures S1D–S1F). These samples
therefore failed our quality control steps and were dis-
carded from further analysis. For the remaining compari-
sons, we also removed two WGS cases whose normal
data had poor quality (Figure S2).
We designed additional computational filters (see
Material and Methods) to remove such artifacts in the re-
maining samples by testing different combinations of
thresholds and comparing the resulting set against WGS
calls. This filtration resulted in high-confidence somatic
calls from WES data with a substantial reduction in the
number of WES-specific calls (Figure S3A). Overall, 61% of
the WES calls were shared by WGS (Figure 1C). Many calls
found in WGS are missed by WES; out of 145 SVs detected
from WGS data with breakpoints in exons (excluding
UTRs), 21% (31/145) were recovered from WES data. This
low rate ismainlydue to the insufficientnumberof support-
ing read pairs (Figure S3B) in addition to the uneven read
coverage in the targeted regions in WES (Figure S3C). The016
Table 1. Summary of Somatic SVs in 15 Tumor Types
Tumor Type Abbreviation Sample Size Bad Samples Good Samples Total SVs
Average SVs
per Sample
Massively
Rearranged
Urothelial bladder cancer BLCA 185 3 182 370 2.03 6
Breast cancer BRCA 781 93 688 3123 4.54 65
Glioblastoma multiforme GBM 318 63 255 626 2.45 24
Head and neck squamous
cell carcinoma
HNSC 377 0 377 413 1.10 4
Clear cell kidney
carcinoma
KIRC 322 13 309 191 0.62 4
Papillary kidney
carcinoma
KIRP 147 0 147 80 0.54 4
Lower grade glioma LGG 272 0 272 218 0.80 6
Liver hepatocellular
carcinoma
LIHC 98 0 98 350 3.57 2
Lung adenocarcinoma LUAD 485 27 458 791 1.73 12
Lung squamous cell
carcinoma
LUSC 460 23 437 837 1.92 9
Prostate adenocarcinoma PRAD 235 1 234 331 1.41 6
Cutaneous melanoma SKCM 311 1 310 577 1.86 24
Stomach adenocarcinoma STAD 234 0 234 570 2.44 11
Papillary thyroid
carcinoma
THCA 485 2 483 342 0.71 0
Uterine corpus
endometrial carcinoma
UCEC 149 24 125 352 2.82 1
Total – 4,859 250 4,609 9,171 1.99 178allele fractions of somatic SVs detected inWES are generally
smaller than those in WGS data (Figure S3D). We suspect
that the exon capture efficiency is lower for the chimeric
DNA molecules that contain the breakpoints, resulting in
lower coverage and hence not enough supporting reads
for detecting SVs. Conversely, it is important to note that
~39% of the WES calls were not found in WGS. At least a
few of these are true positives that were detected by the
higher sequencing coverage in WES data than in WGS
(Figure 1D and Figure S4). The concordance between WES
and WGS calls depends on the quality of the libraries and
may vary among datasets.
To test the accuracy of our calls, we performed PCR on all
high-confidence somatic SVs called from WES data for
which we could obtain the DNA. We found that 78%
(21/27) were validated (Table S2). Overall, these results
suggest that, despite its modest sensitivity, WES-based SV
analysis is likely to yield additional SV candidates that
are biologically meaningful.
A Catalog of Gene Fusions and the Properties of Driver
Fusions
We analyzed WES data for 4,859 cancer samples across 15
tumor types from TCGA (Table 1). A total of 9,171 high-
confidence somatic SVs were detected from 4,609 samples
(Table S3) after excluding 250 samples because of low qual-The Amity. The breast cancers (MIM: 114480) have the highest
number of somatic SVs, whereas the kidney cancers
(both clear cell [MIM: 144700] and papillary cell [MIM:
605074] carcinomas) have the fewest, consistent with
our previous findings6 (Table 1). The genes with somatic re-
arrangements are expressed significantly higher (~2-fold
increase) than the ones without any rearrangements
(Figure S5). Although a previous study16 associated somatic
SV breakpoints with expression, the SV and expression
data came from different sets of samples. Here, we used a
large number of samples that have each undergone both
WES and RNA-seq for a more direct comparison.
Our exome-based SV calling identifiedmany biologically
important variants. Some SVs disrupted tumor suppres-
sors, such as TP53 (MIM: 191170), CDKN2A (MIM:
600160), and PTEN (MIM: 601728) (Table S4). Many SVs
were known driver fusions (examples in Figure 2A). For
example, we detected four RET (MIM: 164761) fusions
(three CCDC6 [MIM: 601985]-RET fusions and one
FKBP15-RET fusion) in thyroid carcinomas, an EML4-ALK
fusion in lung adenocarcinoma, and five FGFR3 (MIM:
134934)-TACC3 (MIM: 605303) fusions in three cancer
types (glioblastoma [GBM], bladder cancer [MIM:
109800], and renal papillary cancer). FGFR3-TACC3 was
originally described in GBM, with 3 out of 97 tumors
examined carrying this fusion.17 This was an importanterican Journal of Human Genetics 98, 843–856, May 5, 2016 847
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Figure 2. Activating Gene Fusions Detected
(A) Exon-specific expression profiles for known cancer-driving fusions.
(B) Exon-specific expression profiles for additional activating fusions. Black arrows in (A) and (B) denote fusion breakpoints. Each box
represents an exon. The expression of each exon was normalized to its average expression across all individuals of the same tumor type.
A gray box indicates that the exon is not expressed in more than 70% of the samples.
(C) Examples of fusion breakpoints at the DNA and RNA level for CEP85L-ROS1, ZNF577-FGFR1, and ROR1-DNAJC6. Green and purple
boxes denote exons of 50 and 30 fusion partners, respectively. Breakpoint junction sequences are shown above the fusions, with letters in
black denoting non-reference sequences. The thick purple line in FGFR1 denotes exonized intronic sequence. The gray box in ROR1 de-
notes the part of the exon being spliced out.discovery because this subset of individuals could poten-
tially benefit from targeted FGFR kinase inhibition. We
had also found the same fusion in about 3% of the bladder
cancer samples, based on analysis of WGS data, as we re-
ported recently in the TCGA consortium paper.18 Our anal-
ysis of the exome data reveals that FGFR3-TACC3 also
occurs in papillary kidney carcinoma. We also detected
two prostate adenocarcinoma (MIM: 176807) cases with
TMPRSS2 (MIM: 602060)-ERG (MIM: 165080) fusions. As
expected, the frequencies of these known drivers are
much lower than the previously reported numbers due to
limited sensitivity. However, we were able to discover a
wide range of variants as a result of the large sample size.
Distinguishing drivers (alterations that increase the
fitness of cells) from passengers (neutral alterations) is848 The American Journal of Human Genetics 98, 843–856, May 5, 2challenging for any type of genetic alteration. For SNVs
and copy-number variants, computational methods (e.g.,
MutSigCV19 and GISTIC,20 respectively) aim to assess the
statistical significance of the observed mutation fre-
quencies by using a background model. Recurrence is the
most obvious factor in estimating the likelihood of fusion
being a driver; however, understanding the molecular
characteristics of driver fusion is critical, given that some
driver fusions have very low frequency, many studies
have small sample sizes, or, as in the case here, detection
sensitivity might be low. Furthermore, recurrent events
can also result from frequent breaks of certain genomic re-
gions such as fragile sites and might not drive cancer. We
previously observed that most of the known driver fusions
are activating fusions and that the 30 fusion partners are016
Table 2. Activating Fusions with 30 Tyrosine Protein Kinases
ID Chr A Breakpoint A Gene A Chr B Breakpoint B Gene B Discord Pair Split Read Homology
THCA-FK-A3SE 10 61655977 CCDC6 10 43611997 RET 13 17 3
THCA-EL-A3ZS 10 61659539 CCDC6 10 43611930 RET 4 4 0
THCA-BJ-A0ZJ 10 61626050 CCDC6 10 43611953 RET 13 5 1
THCA-ET-A3DQ 9 115932783 FKBP15 10 43610457 RET 5 2 3
LUAD-67-6215 2 42491894 EML4 2 29447037 ALK 6 5 2
THCA-EM-A4FR 5 41038833 MROH2B 2 29481156 ALK 7 7 3
GBM-06-5418 6 118801608 CEP85L 6 117642526 ROS1 55 46 4
BRCA-AR-A0U3 19 52383621 ZNF577 8 38317439 FGFR1 104 29 7
BRCA-AR-A0TT 19 16243092 RAB8A 19 4115139 MAP2K2 45 32 0
GBM-06-5411 1 204951828 NFASC 1 156844167 NTRK1 534 398 2
LGG-E1-5319 1 155784108 GON4L 1 156813488 INSRR 29 24 1
Genes on the left denoted by ‘‘Gene A’’ are 50 fusion partners, and genes on the right denoted by ‘‘Gene B’’ are 30 fusion partners.almost always upregulated, typically with expression
change at the fusion breakpoints21,22 (Figure 2A). To iden-
tify activating gene fusions, we thus propose three criteria:
(1) the gene fusion must maintain the same transcription
orientation; (2) the fused 30 partner must be upregulated;
and (3) a significant expression change must be observed
at or near the fusion breakpoints in at least one of the
two source regions (e.g., red versus blue exons on the
two sides of the TACC3 breakpoint in the FGFR3-TACC3
fusion in Figure 2A). There are driver fusions that do not
have an upregulated 30 partner, but these are hard to iden-
tify unless they recur across many samples. Expression
change at the breakpoint was also used to identify fusion
candidates from expression array data, followed by 50 rapid
amplification of cDNA ends to search for the fusion part-
ners.23–25 Using the three criteria above, we uncovered a
total of 150 activating fusions (Table S5). Five activating fu-
sions (CEP85L-ROS1, ZNF577-FGFR1 [MIM: 136350],
ROR1-DNAJC6, SPTBN2 [MIM: 604985]-FGF19 [MIM:
603891], ACACA [MIM: 200350]-HTRA4 [MIM: 610700])
are shown in Figure 2B as examples. We note that these
activating fusions are candidate driver fusions, but the
criteria we used are not sufficient to define them as cancer
drivers. In vitro and in vivo experiments are needed to
definitively address their role in tumorigenesis (see Func-
tional Validation of Fusion Genes In Vitro and In Vivo).
Not surprisingly, GO analysis of the activating fusions
revealed that the 30 fusion partners are enriched for protein
tyrosine kinases (p ¼ 1.7E-4) (Table 2) as previously
observed.26–28 The protein tyrosine kinases RET, ALK,
and ROS1 are known oncogenes and often form fusions
with various partners in lung (MIM: 211980), thyroid,
and colorectal cancers (MIM: 114500)22,29–33 (e.g., for
RET: CCDC6, FKBP15, TBL1XR1 [MIM: 608628], AKAP13
[MIM: 604686], KIF5B [MIM: 602809]; for ALK: EML4,
STRN [MIM: 614765], GTF2IRD1 [MIM: 604318],
MROH2B, C2orf44 [MIM: 616234]; for ROS1: SLC34A2The Am[MIM: 604217], CD74 [MIM: 142790], SDC4 [MIM:
600017], EZR [MIM: 123900], LRIG3 [MIM: 608870]).
Some of the kinase fusions detected fromWESwere known
previously. For instance, NFASC (MIM: 609145)-NTRK1
([MIM: 191315] neurotrophic tyrosine receptor kinase
type 1) was found in two TCGA GBM samples via RNA-
seq data and validated as a cancer driver.34 Other fusions
identified here were not reported previously: for example,
INSRR (MIM: 147671), an insulin receptor-related receptor,
is paralogous to many oncogenes such as ROS1, NTRK1,
and ALK, but has never been described as a fusion partner
in cancer even though it is involved in the AKT and MAPK
signaling pathways and its expression has been correlated
with a favorable prognosis in neuroblastoma.35 The fusion
GON4L (MIM: 610393)-INSRR found in low-grade glioma
activates the protein kinase domain of INSRR, suggesting
that it is likely to be a driver fusion.
We also found that the 50 fusion partners of activating
fusions are often housekeeping genes, such as those related
to the cytoskeleton (p ¼ 7.4E-5) and biosynthesis (p ¼
2.8E-3) (Table S6). For example, CCDC6, FKBP15, and
EML4 are cytoskeleton proteins that fuse to RET and
ALK. Furthermore, both the 50 fusion partners (p ¼
8.5E-3) and the 30 fusion partners (p ¼ 4.9E-3) of the acti-
vating fusions are enriched in chromatin regulators (Tables
S7 and S8). Many of the chromatin regulator fusions occur
in the breast cancer samples. USP21 (ubiquitin specific pro-
tease 21 [MIM: 604729]), which deubiquitinates histone
H2A and removes the transcriptional repression tag, is up-
regulated in 33% of the breast cancer samples.36 KDM2A
(MIM: 605657), a histone demethylase that maintains
heterochromatin and genome stability, and C11orf30
(MIM: 608574), a protein-coding gene that can repress
transcription and might play a central role in the DNA-
repair function of BRCA2 (MIM: 600185), are upregulated
in 17% and 11% of the breast cancer samples, respec-
tively.36 The chromatin regulators are upregulated uponerican Journal of Human Genetics 98, 843–856, May 5, 2016 849
fusions and might alter expressions of many other genes
and play important roles in tumor progression.
Given the functional categories enriched in the fusion
partners, we propose a general model of driver fusions in
cancer. The 30 partners are often oncogenes, which can
promote cell growth and proliferation but are typically
not expressed in differentiated cells. The 50 partners are en-
riched in housekeeping genes, which are expressed in
normal cells but whose production is controlled by various
mechanisms, including negative feedback loops. Upon
fusion, the active housekeeping gene in cancer cells turns
on its oncogenic partner. However, because no house-
keeping protein is produced, the housekeeping genes
remain on. As a result, both the 50 and 30 fusion partners
are upregulated. In the case of TMPRSS2-ERG in prostate
cancers (the predominant recurrent aberration in that tu-
mor type), TMPRSS2 is activated by the androgen receptor
and serves as a housekeeping gene in the prostate tissue.
The 30 fusion partners are different ETS family oncogenes
(e.g., ERG, ETV1 [MIM: 600541], ETV4 [MIM: 600711],
and ETV5 [MIM: 601600])23 that are activated by
TMPRSS2.
With sequencing data available from both DNA and
RNA, it is also possible to interrogate how the fusion genes
are spliced. Three cases are shown in Figure 2C: (1) The
CEP85L-ROS1 fusion occurs between exon 9 of CEP85L
and exon 35 of ROS1. The breakpoints at the DNA level
are out of frame; however, upon alternative splicing (the
fusion exon 9-35 being spliced out), the fusion is in frame
at the RNA level. (2) The ZNF577-FGFR1 fusion is between
exon 4 of ZNF577 and intron 1 of FGFR1. A small portion
of the FGFR1 intron becomes part of an exon through a
cryptic splice site, and the resulting transcript is in frame.
(3) The ROR1-DNAJC6 fusion is between exon 9 of ROR1
and intron 1 of DNAJC6. After fusion, part of the ROR1
exon 9 is spliced out through a cryptic splice site along
with the intron 1 of DNAJC6, resulting in an in-frame tran-
script. These examples illustrate how alternative splicing
and/or cryptic splice sites can be used after gene-fusion
events to produce in-frame transcripts even if the fusions
are out of frame at the DNA level. Therefore, prediction
of functional consequences for gene fusions on the basis
of the DNA sequence must account for these mechanisms.
Functional Validation of Fusion Genes In Vitro and
In Vivo
We performed extensive in vitro and in vivo validation for
two fusions. Various fusions involving the ROS1 receptor
tyrosine kinase have been identified previously, primarily
in non-small cell lung cancer (NSCLC),33 and they
are known to induce cell foci formation and anchorage-
independent growth.37,38 The CEP85L-ROS1 fusion in
particular was reported in angiosarcoma and epithelioid
hemangioendothelioma,25 and we found it in GBM in
our analysis. However, its function in tumorigenesis has
not yet been established. To test the oncogenic potential
of this fusion, we utilized Ba/F3, a murine pro-B cell line850 The American Journal of Human Genetics 98, 843–856, May 5, 2that depends on interleukin-3 (IL-3) for survival and prolif-
eration. Ba/F3’s dependence on IL-3 is readily transferred
to expressed oncogenes, thus representing a sensitive assay
to quantitate oncogenic activity of fusion genes after Ba/F3
transduction and IL-3 removal from growth medium.39–41
Introduction of the CEP85L-ROS1 fusion gene into Ba/F3
cells revealed a robust, >100-fold increase (p < 0.0001) in
survival after IL3 removal in comparison toGFP-expressing
control cells (Figure 3A). Notably, the growth-promoting
activity exhibited by CEP85L-ROS1 was similar to that
of BCR–ABL1, whose oncogenic activity has been well
characterized.42 Next, we delivered CEP85L-ROS1 fusion
into MCF-10A human breast epithelial cells43 which are
widely used in anchorage-independent growth assays to
assess the transforming activity of oncogenes.44 As shown
in Figure 3B, expression of CEP85L-ROS1 in MCF-10A
cells significantly increased colony formation (11-fold,
p < 0.0001), as did the oncogenic PIK3CAH1047R con-
trol.45 We also found that CEP85L-ROS1 expression in
NIH 3T3 murine fibroblasts induced their anchorage inde-
pendent growth and cellular proliferation in vitro (Figures
S6A and S6B) and tumor-forming activity in vivo (Figures
3C and 3D). Immunoblot analysis showed elevated phos-
phorylation of ERK1/2 (T202/Y204) in all three cell lines
(Ba/F3, MCF-10A, and NIH 3T3; Figures S6C–S6E), which
suggested that the MAPK signaling pathway was activated.
We tested the effectiveness of this fusion as a drug target.
Crizotinib is a small molecular protein kinase inhibitor
for ALK and ROS1. It is approved for use in NSCLC cases
with ALK fusion, and it has shown great anti-tumor activ-
ity in clinical trials targeting advanced NSCLC with a ROS1
rearrangement.46 We observed a marked inhibitory activ-
ity of crizotinib on CEP85L-ROS1-transformed Ba/F3 cells
in comparison to parental cells (CEP85L-ROS1 IC50 ¼
0.012 mM; parental IC50 ¼ 0.489 mM) as shown in
Figure 3E. Our results show that individuals harboring a
ROS1 fusion in tumor types other than NSCLC might
also benefit from the ROS1 inhibitor.
Our second candidate fusion for experimental valida-
tion was ROR1-DNAJC6 in lung adenocarcinoma. ROR1
is a receptor tyrosine kinase that modulates neurite
growth in the CNS and might interact with the Wnt
signaling pathway.47 It has not yet been reported as a can-
cer-driving fusion partner. Our experiments showed that
the ROR1-DNAJC6 fusion can promote in vitro cell prolif-
eration in BEAS-2B cells (non-cancerous human bronchial
epithelium; Figures 4A and S7). It can also induce
anchorage-independent cell growth (Figures 4B–4D) in
both BEAS-2B and NIH 3T3 cells, and promote in vivo tu-
mor formation in mice (Figure 4E) as well. Interestingly,
the receptor tyrosine kinase ROR1 is the 50 partner in
this fusion, in contrast to most other fusions in which
protein tyrosine kinases are activated as 30 fusion partners.
Another example with a protein tyrosine kinase on the
50 side is the FGFR3-TACC3 fusion,17 in which FGFR3
loses its 30 UTR and escapes from silencing to promote
cellular growth.016
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Figure 3. Functional Validation of
CEP85L-ROS1
(A) CEP85L-ROS1 expression relieves Ba/F3
cells from dependency on IL-3.
(B) Anchorage-independent colony for-
mation assays for CEP85L-ROS1 in MCF-
10A cells (mean colony count from ten
random areas).
(C and D) The transforming potential of
the CEP85L-ROS1 fusion in vivo. The
tumor volume was calculated with the
modified ellipsoidal formula (volume ¼
1/2 [length 3 width2]) and the greatest
longitudinal diameter (length) and the
greatest transverse diameter (width) were
used. Mice were sacrificed and photo-
graphed on day 23.
(E) Compared to parental cells (IC50 ¼
0.489 mM), CEP85L-ROS1-transformed Ba/
F3 cells are significantly more sensitive
(log-rank test) to crizotinib (IC50 ¼
0.012 mM). Error bars indicate SD.Our results showing the oncogenic potential of these
two fusions demonstrate that previously unknown can-
cer-driving fusions can be detected from WES data,
including some that are potential drug targets.
Massive Rearrangements
A small percentage of cancers might have one or more
chromosomes massively rearranged, often with copy
numbers oscillating between two or three states (chro-
mothripsis),48,49 segments amplified to many copies
(chromoanasynthesis),6,50 or chains of rearrangements
(chromoplexy).51 These rearrangements have been pro-
posed to form through shattering and rejoining of DNA
fragments by non-homologous end joining,48 pulveriza-
tion of chromosomes in the micronuclei,52 and template
switching during DNA replication.6,50 When we searched
for chromosomes with statistically significant enrichment
of SV breakpoints compared to the rest of the genome by
using WES data (taking into account the gene densities
on different chromosomes), we found a total of 196 chro-
mosomes in 178 samples (3.8% of 4,609 samples; Table 1,
Figure 5A, and Table S9). Our statistical threshold was
based on the binomial test with a cutoff of p ¼ 0.01 after
the Bonferroni correction (see Material and Methods);
given this stringent threshold, the number of samples we
report with massively rearranged chromosomes is likely
to be an underestimation.
The frequency of massive rearrangements was highly
variable across chromosomes (Figure 5A), with up to
an ~100-fold difference in the normalized frequencies
(e.g., chr17 versus chrX). The highest frequencies were
found in chromosomes 17 and 22, consistent with a previ-
ous study53 that found amplification breakpoints to beThe American Journal of Humamost frequent on chromosome 17.
Different chromosomes were en-
riched for the SV clusters from di-fferent tumor types (Figure 5B). Chromosomes 7 and 12
are enriched for rearrangements in GBMs, and chromo-
some 22 is enriched for melanomas (MIM: 155600). On
chromosome 17, 23 out of 35 occurrences are in breast can-
cers (examples in Figure 5C), and their breakpoints are
highly abundant at the ERBB2 (MIM: 164870) locus
(Figure 5D). Significantly higher copy numbers and expres-
sion at the ERBB2 locus suggest that the massively rear-
ranged chromosome 17 is associated with upregulation
of oncogene ERBB2 (Figure 5E). Those breast cancers with
any massively rearranged chromosome, as well as those
with massively rearranged chromosome 17 among the
HER2þ subtype, have poorer prognosis with marginal sta-
tistical significance (p ¼ 0.06 and 0.08, respectively;
Figure S8).
There are co-occurrence patterns among the chromo-
somes that have massive rearrangements. For example,
of the nine melanomas with chromosome 22 rearr-
angements, seven involve other chromosomes, including
five involving chromosome 5 (Figures 5F and S9).
Conversely, there are three melanomas with massively
rearranged chromosome 5, and all of them co-occur
with massively rearranged chromosome 22 (Table S9). In
melanoma cases, it is known that ~70% have TERT
([MIM: 187270] on chromosome 5) upregulated by pro-
moter mutations.54,55 We found that the individuals
with massively rearranged chromosome 22 have signifi-
cantly higher expression of TERT when chromosome 5
is also involved (Figure 5G). In GBM, CDK4 (MIM:
123829) is often amplified and expressed at a significantly
higher amount in individuals with massively rearranged
chromosome 12 (Figure S10A). On the other hand, the
expression of EGFR (MIM: 131550) is not significantlyn Genetics 98, 843–856, May 5, 2016 851
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Figure 4. Functional Validation of ROR1-
DNAJC6
(A) Growth rate of cells expressing ROR1-
DNAJC6 fusion protein in BEAS-2B cells.
(B) BEAS-2B cells cultured in Matrigel after
7 days and NIH 3T3 cells cultured in soft
agar after 14 days expressing ROR1-
DNAJC6 fusion protein. Scale bar, 50 mm.
(C and D) Anchorage independent growth
in soft agar. BEAS-2B or NIH 3T3 cells
transformed with ROR-DNAJC6 were
cultured in soft agar for 21 days.
(E) The transforming potential of ROR1-
DNAJC6 fusion in vivo.different in individuals with massively rearranged chro-
mosome 7 because the ones without massively rearranged
chromosome 7 also have EGFR amplifications (Fig-
ure S10B). This is consistent with our previous study6
showing that most (14 out of 16) GBM samples have
EGFR amplified and that some of the amplifications are
achieved through very complex rearrangements. These
results suggest that massive rearrangements are often
associated with upregulation of oncogenes, which pro-
vides selective advantage to the cells, and these rearrange-
ments are thus maintained in the genome.Discussion
Here, we report the somatic genome rearrangements de-
tected in the WES data for nearly 5,000 human cancer
samples. WES data present challenges for SV identifica-
tion, with ligation artifacts formed during exome capture
and/or DNA amplification steps often manifesting as
small tandem duplications. Many of the samples we
excluded on the basis of quality were whole-genome
amplified (WGA) samples, but other WGA samples did
not suffer from the same problem. Although it is not
possible to determine whether a specific tandem duplica-852 The American Journal of Human Genetics 98, 843–856, May 5, 2016tion is a true or artifactual one,
their genome-wide distribution is
strongly indicative of the sample
data quality. The large number of
samples with both WES and WGS
data allowed us to set proper
filtering thresholds.
SV identification based on WES
data has much lower sensitivity than
that based on WGS data. Therefore,
it is not sensible to generate WES
data to profile SVs or to replace WGS
with WES. Our goal here was to re-
analyze existing WES data, given
that the number of samples with
WES data is larger than that with
WGS by an order of magnitude. In
TCGA, for example, almost all of thesamples were profiled by WES, whereas about 10% of the
cases were profiled by WGS.
The number of exomes sequenced will continue to grow,
especially as we search for somatic mutations with low
variant allelic frequency. For instance, some somatic driver
SNVs in cancer have been shown to occur in <5% of the
cells. In neuroscience, there is now a great deal of interest
in identifying somatic mutations in the brain to poten-
tially explain neurological diseases such as epilepsy and
developmental brain malformations.56 For such variants,
high-coverage WES will be the preferred platform for
most investigators until WGS at very high coverage be-
comes more affordable. Identification of even a fraction
of the SVs in these datasets will be valuable. As we showed
in one example (Figure 1D), somatic SV with low variant
allele frequency cannot be detected by WGS as a result of
its much lower coverage than WES. Importantly, the
framework we described here is also applicable to germline
rearrangements, and the number of germline exomes from
individuals with a variety of disease phenotypes as well as
from healthy individuals is already enormous.
As another application of exome-based SV analysis, we
investigated massive rearrangements in our cohort and
found that WES data can capture the presence of these
events and their association with other factors. Because
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Figure 5. Massive Rearrangements Are
Often Associated with Upregulation of
Oncogenes
(A) The frequencies of massively rear-
ranged chromosomes normalized by the
uniquely mappable size of CDS in each
chromosome.
(B) The frequencies of massively rear-
ranged chromosomes colored by tumor
type.
(C) Examples of two breast cancers with
massively rearranged chr17. Blue and red
lines denote intra-chromosomal and in-
ter-chromosomal rearrangements, respec-
tively.
(D) The breakpoint distribution of
massively rearranged chr17 of breast can-
cers with the peak at ERBB2.
(E) Association (Wilcoxon one-side rank
test) of massive rearrangements with
copy change and expression of ERBB2 in
breast cancers. NMR, not massively rear-
ranged; MR, massively rearranged. Error
bars indicate SD.
(F) An example of massively rearranged
chr22 that involves chr5 in melanoma.
(G) Association (Wilcoxon one-side rank
test) of massively rearranged chr22 with
TERT expression. Group 1 includes mela-
nomas with massively rearranged chr22
that involves chr5. Group 2 includes mela-
nomas with massively rearranged chr22
that does not involve chr5 with wild-type
TERT promoter. Error bars indicate SD.these events are rare (~4% of the cases), their enrichment
in specific chromosomes or tumor types, as well as their
correlations with copy number and gene expression,
became apparent with a large sample size (hundreds of
samples per tumor type). Our finding that massive
rearrangements are often associated with oncogene
upregulation would not have been possible from WGS
data. Copy-number profiles from microarray have been
used to detect chromothripsis events on the basis of
oscillating copy numbers on one or more chromo-
somes,48 including in our own work.57 However, inter-
chromosomal events cannot be detected from arrayThe American Journal of Humaprofiles, and the association between
chromosome 22 massive rearrange-
ments and upregulation of TERT
could only be detected with WES
data. Overall, our study of somatic
genome rearrangements utilizing
WES data provides insights into how
gene fusions drive cancer and demon-
strates the utility of re-analyzing ex-
isting data.
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